Ameriprise’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q3
Sell
-168,646
Closed -$3.03M 3839
2020
Q2
$3.03M Buy
168,646
+157,714
+1,443% +$2.19M ﹤0.01% 2391
2020
Q1
$78K Sell
10,932
-13,949
-56% -$174K ﹤0.01% 3557
2019
Q4
$593K Sell
24,881
-5,085
-17% -$140K ﹤0.01% 3274
2019
Q3
$804K Sell
29,966
-23,226
-44% -$652K ﹤0.01% 3107
2019
Q2
$1.44M Sell
53,192
-25,115
-32% -$788K ﹤0.01% 2915
2019
Q1
$2.72M Buy
78,307
+45,509
+139% +$1.31M ﹤0.01% 2594
2018
Q4
$640K Buy
+32,798
New +$674K ﹤0.01% 3114
2018
Q3
Sell
-5,783
Closed -$218K 3814
2018
Q2
$218K Buy
+5,783
New +$221K ﹤0.01% 3462
2018
Q1
Sell
-32,000
Closed -$1.56M 3734
2017
Q4
$1.56M Buy
32,000
+528
+2% +$26.7K ﹤0.01% 2777
2017
Q3
$1.7M Buy
31,472
+98
+0.3% +$5.75K ﹤0.01% 2694
2017
Q2
$1.76M Buy
+31,374
New +$1.26M ﹤0.01% 2668
2016
Q1
Sell
-87,693
Closed -$4.51M 3923
2015
Q4
$4.51M Buy
87,693
+12,246
+16% +$594K ﹤0.01% 2082
2015
Q3
$3.22M Buy
75,447
+33,464
+80% +$1.61M ﹤0.01% 2310
2015
Q2
$1.91M Buy
+41,983
New +$1.69M ﹤0.01% 2788
2013
Q4
Sell
-604
Closed -$16K 5520
2013
Q3
$16K Hold
604
﹤0.01% 4580
2013
Q2
$15K Buy
+604
New +$12K ﹤0.01% 4505

Ameriprise's PTLA Position: Q3 2020 in Review

Ameriprise sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2020, closing a stake of 168,646 shares — an estimated $3.03M sold.

Ameriprise first reported a position in PTLA in Q2 2013 and held it in 16 quarters. The position peaked at $4.51M in Q4 2015. 0 funds tracked by Wall St. Rank hold PTLA as of Q3 2020.

  • Ameriprise reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
  • Ameriprise sold 168,646 Portola Pharmaceuticals, Inc. shares in Q3 2020, an estimated $3.03M.
  • Ameriprise first reported a position in Portola Pharmaceuticals, Inc. in Q2 2013 and held it in 16 quarters.
  • Ameriprise's Portola Pharmaceuticals, Inc. position peaked at $4.51M in Q4 2015.
  • 0 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2020.

Based on Ameriprise's 13F filing for Q3 2020, filed 16 Nov 2020.